ArticleThe FEBS journal2026
Investigating transthyretin variants H88R and I107V in amyloid priming: From destabilization to complete dissociation.
Article in The FEBS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Structural Hierarchy and Maturation of Amyloid Fibrils Revealed by Interface Descriptor Analysis.Journal of chemical information and modeling · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The destabilization of transthyretin (TTR) tetramers underlies the pathogenesis of ATTR amyloidosis, a disease manifesting in form of toxic amyloid deposits. Here we investigate two clinically relevant TTR variants, H88R and I107V, found among ATTR patients in the Carpathian Basin. While the I107V mutation exerts only a mild effect on tetramer assembly and monomer stability, it decreases the denaturation midpoint and enhances aggregation propensity at physiological pH, against both wild-type and monomeric TTR (MTTR) backgrounds. Structural analysis revealed that the absence of the methyl group of residue 107 perturbs the hydrophobic trapping of F87 across the primary tetramerization interface. We also found that the far more disruptive H88R mutation that fully abolishes tetramer formation and yields a highly amyloidogenic monomer also acts through the disarray of the F87-centered inter-chain contact. Its equilibrium ensemble includes unfolded components and displays reduced denaturation entropy, traits suggestive of a primed aggregation-prone state. Simulations reveal that the H88R mutation leads to the partial disordering of the EF helix/loop, which in wild-type TTR participates in a Trp-cage-like architecture (centered on W79) shielding the hydrophobic core of the monomeric form. Our results suggest that the H88R variant may serve as a more physiologically relevant model of aggregation-prone TTR than the widely used MTTR double mutant, which does not show amyloidogenic propensity at physiological pH. Based on their physicochemical properties and position with respect to the determined interaction loci, we offer explanation for the phenotypic presentation of D18G, A25T, and Y114H and H88R monomerizing mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.